Supplements With Evidence In Mild Cognitive Impairment
Quick Read Mild cognitive impairment is a grey zone between normal age-related memory changes and dementia, and it may be
Subscribe to the distribution list, to get regular updates on supplement research for health,
🧠 NeuroBright Our evidence-based brain supplement formulated from 1.7M research papers
Omega-3 fatty acids appear to help rheumatoid arthritis by reducing inflammation in the joints, but the benefits are modest rather than dramatic. A large analysis of 23 studies found small improvements in pain, joint swelling, and inflammation markers, though the quality of evidence was rated low. One longer 18-month study showed more meaningful disease activity reductions and allowed patients to use less heavy-duty RA medication.
An equally important benefit may be cardiovascular protection. People with RA face significantly elevated heart disease risk, and omega-3 consistently improves cholesterol levels and reduces blood clotting tendency in this population, which is a substantial secondary reason to supplement beyond any joint benefit.
If you choose to take omega-3 for RA, evidence suggests doses matter: roughly 2-4 grams of EPA and DHA daily appears more effective than lower doses. Omega-3 is safe and inexpensive, but should complement, not replace, prescribed RA medications under medical supervision.
Verdict: Omega-3 is not a cure for RA, but it offers modest joint benefits plus important cardiovascular protection, making it a reasonable addition to comprehensive RA treatment at appropriate doses.
What if the fish oil capsule sitting in your kitchen cupboard isn’t quite the miracle joint remedy you were hoping for, but isn’t useless either? If you have rheumatoid arthritis, or know someone who does, you’ve almost certainly heard the advice: take omega-3. It’s the kind of recommendation that gets passed around at dinner parties, printed in wellness magazines, and repeated so often it feels like settled science. But when you actually sit down with the research, which is what we do at Vitacuity, having analysed over 1.77 million papers and selected the most relevant for this topic, the picture is considerably more interesting, and considerably more honest, than the headlines suggest. Omega-3 fatty acids do something real in the body when it comes to inflammation. The question is whether “something real” translates into “something clinically meaningful” for people living with RA. The answer, it turns out, depends heavily on what you’re hoping for, what dose you’re taking, and what you’re measuring.
To understand what omega-3 might do for rheumatoid arthritis, you need a brief tour of what RA actually is. It’s not just “achy joints.” RA is a chronic autoimmune disease, the immune system mistakenly attacks the synovium (the lining of the joints), flooding it with immune cells and triggering a persistent inflammatory cascade that, over time, erodes cartilage and bone [14]. The key players in this destruction are pro-inflammatory molecules called cytokines (including TNF-alpha and IL-6), eicosanoids derived from arachidonic acid, and an overactive T-helper-1 immune response [14].
This is where omega-3 enters the picture. The two marine omega-3 fatty acids, EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid), are well-established anti-inflammatory and immunomodulatory agents [11]. They work through several mechanisms at once. First, they compete with arachidonic acid (the raw material for many inflammatory molecules) for the same enzymes, effectively crowding it out and reducing the production of inflammatory eicosanoids [14]. Second, they modulate immune cell function and cytokine production, dialling down the signalling that drives RA’s characteristic inflammation [3].
But here’s the more exciting, and still emerging, piece of the biology. EPA and DHA aren’t just passive blockers of bad signals. They’re the raw materials for a class of molecules called Specialised Pro-Resolving Mediators, or SPMs [5]. These include lipoxins, resolvins and protectins, and their job isn’t just to suppress inflammation, it’s to actively resolve it and restore tissue homeostasis. In healthy physiology, inflammation is supposed to switch itself off; SPMs are the “off switch.” Research now suggests that in RA, this resolution process may be dysfunctional, meaning the body isn’t producing enough SPMs to shut inflammation down, and that omega-3 supplementation may help restore it [5]. This is a relatively new and genuinely exciting avenue of research, though it’s still finding its clinical footing.
Evidence grade: Conflicted, multiple RCTs exist, but effect sizes are small and evidence quality is rated low to very low by researchers.
Let’s start with the most comprehensive evidence we have. A 2024 systematic review and meta-analysis pooled data from 23 randomised placebo-controlled trials of omega-3 supplementation in RA patients [1]. This is about as robust a dataset as the field has produced. The findings were honestly rather sobering: omega-3 supplementation produced only small effects across the main outcomes measured. Pain was reduced by a standardised mean difference of just -0.16 (on a statistical scale where 0.2 is considered “small” and 0.5 “medium”). Tender joint count came in at -0.20 and swollen joint count at -0.10. C-reactive protein, a key blood marker of inflammation, was reduced by just 0.21 mg/dL. The reduction in NSAID (anti-inflammatory painkiller) use showed a small effect too (SMD: -0.22), but the authors flagged this finding as potentially biased by inadequate blinding in some of the original trials [1].
Crucially, the authors rated the certainty of the evidence as “very low to low” across most outcomes. That doesn’t mean omega-3 does nothing, it means the trials have been inconsistent enough, and sometimes small enough, that we can’t be confident in the precise size of the benefit [1].
A 2025 meta-analysis looking at omega-3 and vitamin D in RA similarly found beneficial effects on inflammatory pathways and clinical symptoms, with the two nutrients appearing to work complementarily through overlapping anti-inflammatory mechanisms [2]. This adds weight to the idea that omega-3 belongs in a broader nutritional strategy for RA management, rather than as a standalone silver bullet.
Evidence grade: Promising, a well-designed randomised double-blind trial with a meaningful duration, though it lacked a true placebo control.
One of the most interesting individual studies in this field is an 18-month randomised double-blind trial published in 2014 [8]. Researchers compared three conditions: fish oil alone (rich in EPA and DHA), borage seed oil alone (rich in gamma-linolenic acid, a beneficial omega-6), and a combination of both. The headline finding might surprise you. All three groups showed significant and clinically meaningful reductions in disease activity. At nine months, DAS28 scores, a standard measure of RA disease activity, fell by -1.56 in the fish oil group, -1.33 in the borage oil group, and -1.18 in the combination group [8]. These are not trivial numbers. When all study patients were compared to matched patients from an RA registry, their disease activity reductions were comparable, and the study patients were actually able to reduce their use of DMARDs (disease-modifying antirheumatic drugs, the heavy-duty RA medications) to a significantly greater extent than registry patients (P < 0.03) [8].
The absence of a no-treatment control group is a genuine limitation here, we can’t rule out that some improvement was the natural course of the disease or a placebo effect. But the DMARD reduction finding is notable, and the 18-month duration gives these results more credibility than shorter studies.
Evidence grade: Promising, consistent findings across the same 18-month trial, supported by plausible mechanism.
There’s something important that gets overlooked in most discussions of omega-3 and RA: people with rheumatoid arthritis face a cardiovascular disease risk comparable to patients with diabetes, 1.5 to 3 times that of the general population [9]. This gap in mortality is largely attributable to CVD, driven in part by the chronic low-grade systemic inflammation that RA creates.
The same research group that ran the 18-month joint study also measured what happened to the participants’ blood lipids [9]. Across all three groups (fish oil, borage oil, and combination), significant improvements in lipid profiles emerged at both nine and 18 months. Total cholesterol, LDL-cholesterol, and triglycerides all fell. HDL-cholesterol (the “good” kind) increased. The atherogenic index, a measure of cardiovascular risk, improved. All these improvements persisted at 18 months (P < 0.001 versus baseline) [9].
For someone managing RA, this is a genuinely important finding. Even if omega-3’s joint benefits are modest, a meaningful improvement in cardiovascular risk markers in a population at elevated CVD risk is a substantial additional reason to consider supplementation.
Evidence grade: Promising, small prospective study (60 patients), 90 days, single centre.
A 2019 study of 60 RA patients at a Serbian rheumatology centre added another piece to the cardiovascular puzzle [13]. Patients were divided into three groups: concentrated fish oil alone, fish oil combined with evening primrose oil, or no supplementation, over three months. The fish oil-only group showed significantly lower platelet aggregation, measured by the ADP/TRAP ratio, compared to the control group (0.68 ± 0.20 versus 0.83 ± 0.12; P = 0.008) [13]. Reduced platelet aggregation means blood is less prone to forming clots, which matters enormously for cardiovascular health. The authors noted that this anti-platelet effect may represent a meaningful preventive strategy for the cardiovascular complications that disproportionately affect people with RA [13].
This is a small study and shouldn’t be overstated. But it adds biological coherence to the broader picture: omega-3 in RA isn’t only (or perhaps even primarily) a joint story, it’s a whole-body inflammatory and cardiovascular story.
Evidence grade: Promising, one well-controlled double-blind trial, 66 patients, 4 months.
One of the most practically useful findings comes from a 2004 double-blind placebo-controlled trial of 66 RA patients, 55 of whom completed the study [12]. Participants received a daily supplement containing 1.4g EPA, 0.211g DHA, 0.5g GLA and various micronutrients, or a placebo, for four months. Result? No significant improvements in tender joint count or any other clinical parameter compared to placebo [12].
Before you conclude that omega-3 simply doesn’t work, read the authors’ interpretation: the study adds information regarding “doses of omega-3 fatty acids, below which anti-inflammatory effects in RA are not seen.” In other words, 1.4g EPA may simply not be enough. The participants’ blood levels of EPA and DHA did increase significantly, their bodies were absorbing the supplement, but the dose wasn’t sufficient to move the clinical needle [12]. This is a critical piece of context when interpreting the wider literature. Many studies showing modest or null results may be testing doses that are pharmacologically insufficient.
Evidence grade: Early stage for clinical applications, strong mechanistic basis, but human trials translating this into RA treatment are still emerging.
The specialised pro-resolving mediators story deserves its own section, because it may reframe how we think about omega-3’s role in inflammatory disease entirely. A 2024 review makes the case that in RA, the body’s natural inflammation-resolution machinery is dysregulated, the production of SPMs (which include resolvins, protectins and lipoxins, all synthesised from EPA and DHA) is insufficient or disrupted [5]. Where conventional thinking focused on omega-3 suppressing inflammation, the SPM framework suggests that the more important action might be actively restoring the body’s capacity to resolve inflammation and repair tissue.
A 2023 study explored whether over-the-counter fish oil supplements, the kind most people actually buy, meaningfully raise circulating SPM levels in RA patients [6]. The findings added nuance: having a chronic inflammatory disease like RA appears to influence how the body metabolises omega-3 into SPMs, which may explain why RA patients sometimes show different responses to supplementation than healthy individuals [6]. This is an important reminder that RA is not a simple inflammatory condition and that individual variation in response to omega-3 may be biologically rooted, not just a matter of compliance or dose.
Evidence grade: Early stage, animal studies only, human trials needed.
Two animal studies in this dataset are worth mentioning, not because they prove anything in humans, but because they point in interesting directions for future research. A 2025 mouse study found that combining omega-3 PUFAs with soluble epoxide hydrolase inhibitors (sEHi, compounds that prevent the breakdown of beneficial anti-inflammatory metabolites derived from omega-3) produced a marked inhibition of arthritis, significantly more than either intervention alone [4]. The study also found an interesting correlation between gut microbiome composition (specifically higher levels of the bacterium Lactococcus) and lower arthritis scores, suggesting the gut microbiome may modulate omega-3’s effects on RA even before disease onset [4].
A 2010 study compared krill oil (a different source of omega-3, where EPA and DHA are bound to phospholipids rather than triglycerides) to standard fish oil in an animal arthritis model [15]. The study found krill oil to be protective against experimental arthritis. Whether this translates to humans, and whether the phospholipid form of omega-3 is meaningfully superior in bioavailability for RA patients, remains an open and interesting clinical question.
Let’s be genuinely honest about the gaps here, because there are significant ones.
Dose: The field still lacks consensus. Studies have used wildly different doses, from under 1g to over 5g of EPA+DHA per day. The 2004 trial suggests there’s a threshold below which nothing happens [12], but we don’t know exactly where that threshold sits, and whether it varies by individual, disease severity, or background diet [14].
Duration: Are months enough, or do we need years? Most trials run for 12-24 weeks. The 18-month trial [8] is an exception, and it showed ongoing improvements, which raises the question of whether shorter trials simply fail to give omega-3 enough time to work. Inflammation resolution is a slow biological process.
Evidence quality is a real concern. The largest meta-analysis rated most of its included evidence as “very low to low” quality [1]. This doesn’t mean the individual trials were badly run, it reflects inconsistency across studies, small sample sizes, and methodological variation. It means we should be appropriately humble about precision.
The blinding problem. Fish oil has a distinctive taste and smell that makes it genuinely difficult to blind participants and researchers. Several studies have been criticised for inadequate blinding, which can introduce bias, particularly in subjective outcomes like pain scores [1].
SPMs in humans: still emerging. The specialised pro-resolving mediator framework is biologically compelling, but its direct clinical translation in RA patients, what doses, what forms of omega-3, what measurable benefits, is still being worked out [5, 6].
Krill oil vs. fish oil: The animal data on krill oil is interesting, but human trials comparing forms of omega-3 directly in RA patients are limited [15].
Individual variation: People with RA vary enormously in their omega-3 metabolism, their gut microbiome, their baseline dietary intake, and their background medication. Trials that pool all RA patients together may be obscuring meaningful responder subgroups [4, 6].
So here’s what a sensible, informed person should actually do with all of this.
Omega-3 is not a cure for rheumatoid arthritis. Anyone who tells you otherwise hasn’t read the literature carefully. The clinical effect sizes from the meta-analyses are small, and the evidence quality is rated low [1]. That is the honest truth, and you deserve to hear it plainly.
But “not a cure” and “not worth taking” are very different conclusions, and conflating them would be a mistake.
Here’s the practical reasoning: omega-3 supplementation at meaningful doses is safe, widely available, and inexpensive. The cardiovascular benefit in RA patients is a separate and genuinely compelling argument, people with RA die prematurely of cardiovascular disease at alarming rates, and omega-3 consistently improves lipid profiles and reduces platelet aggregation in this population [9, 13]. That alone may justify supplementation, independent of any joint benefit.
On the joint side, the 18-month trial showed clinically meaningful disease activity reductions and reduced reliance on heavy-duty RA medications, not across all studies, but in a well-run, real-world-duration trial [8]. The 2025 meta-analysis similarly found beneficial effects [2]. The effect may be modest, but “modest and safe and cheap” beats “modest and expensive and risky” every time.
On dose: The evidence suggests that low doses (around 1.4g EPA) may be insufficient [12]. Most researchers working in this area use doses of 2-4g EPA+DHA daily in RA studies. If you’re going to supplement, a dose in that range is more likely to be biologically meaningful than a standard off-the-shelf 1g capsule.
On form: Omega-3 is omega-3, whether from fish oil or krill oil. The krill oil data is interesting but currently animal-only [15]. A high-quality fish oil standardised for EPA and DHA content is the evidence-supported choice.
On expectations: Think of omega-3 as part of a comprehensive strategy, alongside whatever medical treatment your rheumatologist has prescribed, not as a replacement for it. The 18-month trial participants who did best were still on conventional RA medications; they just needed less of them [8]. That’s a meaningful outcome, but it requires medical supervision to manage.
The bottom line: If you have RA, a daily omega-3 supplement providing 2-3g of EPA+DHA is safe, has a plausible and well-understood mechanism, shows modest clinical benefit in the better-designed trials, and carries meaningful cardiovascular benefits that are independently important for your population. The risk of supplementing is very low. The potential benefit, even if modest on the joint front, is real. A sensible, informed person would supplement. Just don’t throw away your prescription.
[1] Efficacy of n-3 fatty acid supplementation on rheumatoid arthritis’ disease activity indicators: a systematic review and meta-analysis of randomized placebo-controlled trials. (2024). DOI: 10.1080/10408398.2022.2104210 | https://pubmed.ncbi.nlm.nih.gov/35900212/
[2] Evaluation of the Clinical Outcomes Associated With the Use of Fatty Acids and Vitamin D in Rheumatoid Arthritis Patients: A Systematic Review and Meta-Analysis. (2025). DOI: 10.1002/fsn3.70473 | https://pubmed.ncbi.nlm.nih.gov/40692609/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12278022/
[3] Over-the-Counter Anti-inflammatory Supplements for Adjunctive Rheumatoid Arthritis Therapy: A Comprehensive Narrative Review. (2024). https://pubmed.ncbi.nlm.nih.gov/38377032/
[4] Anti-arthritic effects of polyunsaturated fatty acid-rich supplementation combined with selective soluble epoxide hydrolase inhibitors in a collagen-induced arthritis mouse model. (2025). DOI: 10.1093/mr/roaf019 | https://pubmed.ncbi.nlm.nih.gov/40048675/
[5] The role of specialized pro-resolving mediators (SPMs) in inflammatory arthritis: A therapeutic strategy. (2024). DOI: 10.1016/j.prostaglandins.2023.106798 | https://pubmed.ncbi.nlm.nih.gov/37977352/
[6] Over-the-counter fish oil supplementation and pro-resolving and pro-inflammatory lipid mediators in rheumatoid arthritis. (2023). https://pubmed.ncbi.nlm.nih.gov/36773395/
[7] Clinical Benefits of n-3 PUFA and ɤ-Linolenic Acid in Patients with Rheumatoid Arthritis. (2017). https://pubmed.ncbi.nlm.nih.gov/28346333/
[8] Treatment of rheumatoid arthritis with marine and botanical oils: an 18-month, randomized, and double-blind trial. (2014). https://pubmed.ncbi.nlm.nih.gov/24803948/
[9] Treatment of rheumatoid arthritis with marine and botanical oils: influence on serum lipids. (2011). https://pubmed.ncbi.nlm.nih.gov/22007257/
[11] The Role of Marine n-3 Polyunsaturated Fatty Acids in Inflammatory-Based Disease: The Case of Rheumatoid Arthritis. (2023). DOI: 10.3390/md22010017 | https://pubmed.ncbi.nlm.nih.gov/38248642/ | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10817514/
[12] Nutrient supplementation with polyunsaturated fatty acids and micronutrients in rheumatoid arthritis: clinical and biochemical effects. (2004). DOI: 10.1038/sj.ejcn.1601883 | https://pubmed.ncbi.nlm.nih.gov/15164103/
[13] Influence of different supplementation on platelet aggregation in patients with rheumatoid arthritis. (2019). DOI: 10.1007/s10067-019-04569-3 | https://pubmed.ncbi.nlm.nih.gov/31076942/
[14] Polyunsaturated fatty acids and rheumatoid arthritis. (2001). DOI: 10.1097/00075197-200103000-00006 | https://pubmed.ncbi.nlm.nih.gov/11224655/
[15] Supplementation of diet with krill oil protects against experimental rheumatoid arthritis. (2010). https://pubmed.ncbi.nlm.nih.gov/20587038/
This article is for informational purposes only and does not constitute medical advice. Food supplements should not be used as a substitute for a varied and balanced diet and healthy lifestyle. If you are pregnant, breastfeeding, taking medication or have a medical condition, consult your doctor before taking any supplement. These statements have not been evaluated by the Food and Drug Administration (FDA) or the Medicines and Healthcare products Regulatory Agency (MHRA). This product is not intended to diagnose, treat, cure, or prevent any disease.
Quick Read Mild cognitive impairment is a grey zone between normal age-related memory changes and dementia, and it may be
Quick Read Your brain has a nightly cleaning system called the glymphatic system that removes toxic waste proteins during deep
